Advertisement Pharmaceutical Business review - Page 1224 of 5293 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 8, 2026

FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer

The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.

The regimen is indicated for adults with unresectable locally advanced or metastatic HER2+ disease following induction treatment. Credit: Arif biswas/Shutterstock.com.